Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease

Reuters12-03

Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease

Biogen Inc. and Eisai Co., Ltd. have announced new data confirming the pharmacological effect of LEQEMBI® (lecanemab-irmb), an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid $(CSF)$. The results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37559) on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588069115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588069115","market":"fut","top_or_hot":-1,"title":"Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen Inc. and <a href=\"https://laohu8.com/S/ESAIY\">Eisai Co., Ltd.</a> have announced new data confirming the pharmacological effect of LEQEMBI® (lecanemab-irmb), an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid <a href=\"https://laohu8.com/S/CSF\">$(CSF)$</a>. The results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37559) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 05:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen Inc. and <a href=\"https://laohu8.com/S/ESAIY\">Eisai Co., Ltd.</a> have announced new data confirming the pharmacological effect of LEQEMBI® (lecanemab-irmb), an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid <a href=\"https://laohu8.com/S/CSF\">$(CSF)$</a>. The results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37559) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLN78rq:1","article_id":"2588069115","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588069115","pubTimestamp":1764711657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biogen Inc. and Eisai Co., Ltd. have announced new data confirming the pharmacological effect of LEQEMBI , an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid . The results were presented at the 18th Clinical Trials on Alzheimer's Disease  Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4139":"生物科技","BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Biogen宣布新数据证实LEQEMBI可减少阿尔茨海默病中的神经毒性淀粉样原纤维","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"Biogen Announces New Data Confirming LEQEMBI Reduces Neurotoxic Amyloid Protofibrils in Alzheimer's Disease\n    \n\n        Biogen Inc. and Eisai Co., Ltd. have announced new data confirming the pharmacological effect of LEQEMBI® (lecanemab-irmb), an anti-Aβ protofibril antibody, on neurotoxic Aβ protofibrils in cerebrospinal fluid $(CSF)$. The results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in 2025. The study showed that lecanemab treatment led to a significant increase in total CSF protofibril concentration at 12 months compared to placebo, suggesting target engagement and mobilization of protofibrils from the brain parenchyma into the CSF. This data supports the pharmacodynamic effect of lecanemab in patients with Alzheimer's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY37559) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588069115","isCrawlerRequest":true}